Market Overview

CareDx Reported Positive Clinical Results For Its Kidney Transplant Blood Tests


CareDx, Inc. (NASDAQ: CDNA) revealed promising clinical performance of its AlloSure assay for the non-invasive surveillance of kidney transplant rejection, according to a note from analysts at Janney.

In patients studied as part of a DART clinical trial, CareDx’s “AlloSure” blood assay successfully detected heightened levels of donor-derived cell free DNA in subjects presenting kidney transplant rejection.

More details could follow if AlloSure is presented during kidney week at the American Society of Nephrologists this fall. Leveraging on the company's transplantation expertise and existing relationships cultivated over a multi-year period, cross-selling opportunities and new product rollouts may drive revenue acceleration starting in 2017.

CareDx closed up 2 percent at $5.04.

Latest Ratings for CDNA

May 2019UpgradesNeutralBuy
Mar 2019MaintainsStrong BuyStrong Buy
Feb 2019Initiates Coverage OnBuy

View More Analyst Ratings for CDNA
View the Latest Analyst Ratings

Posted-In: JanneyAnalyst Color Biotech Health Care Analyst Ratings General


Related Articles (CDNA)

View Comments and Join the Discussion!

Latest Ratings

BCELInitiates Coverage On23.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Court Releases Texts Between Former Goldman Employee And Prostitute For Potential Client

4 Stocks Moving In Thursday's After-Hours Session